logo-loader
Arix Bioscience PLC

Arix Bioscience forms collaboration with Evotec AG and prominent cancer research center

Arix Bioscience Plc (LON:ARIX) Chairman Jonathan Peacock and Investment Director Daniel O'Connell tell Proactive Investors the health care and life science company has formed LAB591, an academic "BRIDGE" collaboration with the Fred Hutchinson Cancer Research Center in Seattle, Washington, and drug discovery alliance and development partnership company Evotec AG (OTCMKTS:EVTCY).

According to Arix, LAB591 aims to accelerate research discoveries at Fred Hutch and use these discoveries to form new companies focused on cancer and infectious disease drug development.

Quick facts: Arix Bioscience PLC

Price: £1.20

Market: LSE
Market Cap: £162.66 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Arix Bioscience 'building a very exciting, diversified healthcare company'

Dr Joe Anderson, chief executive of Arix Bioscience Plc (LON:ARIX) runs Proactive Investors through the company's strategy and outlook. ''We're focused on the innovation end of healthcare, which is exactly where we believe the value is in healthcare today'', Anderson says.

on 19/5/17

2 min read